A standard acute toxicity study was undertaken to assess 2'-deoxyribonucleoside cyanoboranes for therapeutic safety. 2'-Deoxyribonucleoside cyanoboranes and related derivatives were nontoxic at doses required for anti-neoplastic and hypolipidemic activities. LDs0 values were greater than 1000 mg/kg, IP, for all compounds.
Introduction 2'-Deoxyribonucleoside cyanoboranes have been investigated for eytotoxic activity against murine and human tumor cell growth, and for their anti-neoplastic activity against murine tumors [1, 2] . They have also recently been observed to be hypolipidemic agents, significantly inhibiting enzymes involved in de novo lipid synthesis [3] . Moreover, these same derivatives were recently shown to protect against LPS-induced septic shock. The guanine and cytidine derivatives have proven to be pharmacologically more active than some of the other bases, inosine, adenine, or thymidine [ 1 ] . The 8 and 20 mg/kg/day doses used in these pharmacological screens demonstrated no deleterious effects in intact animals [1] [2] [3] . Thus we have selected 20 mg/kg as the standard therapeutic dose. Because of their possible therapeutic value, five 2'-deoxyribonucleoside cyanoboranes were selected to assess acute toxicity in mice in vivo. Deleterious effects were evaluated at dosage levels of 20, 50, and 100 mg/kg and also in HCT-8 human ileum mucosa cells grown in tissue culture.
Materials & Methods
Compounds _1-_5 ( Fig. 1 ), have been synthesized previously; chemical and physical characteristics have been reported [1, 2] . Suspensions of compounds were prepared by homogenizing them in 0.05% Tween 80/H20. Controls received injections of vehicle throughout the 7-day experiment. Vol. I, No. I, 1993 An Investigation of 2'-Deoxyribonucleoside Cyanoboranes in Mice for (No. 587 and Arsen A20 111), and alkaline phosphatase (AP, No. 104) . Serum cholesterol was determined by the method of Ness et al. [5] . Serum triglycerides were determined with a diagnostic kit from Boehringer Mannheim (Diagnostics, Indianapolis, IN, USA). Uric acid and cholic acid were determined as outlined by Tietz [6] .
Albumin and total protein were determined by the method ofLowry, et . [7] .
After blood was obtained from the carotid artery of each CF 1 mouse, it was placed on a glass slide and fixed in Wright's stain. Differential white blood cell counts, platelet counts and hematocrits were obtained aRer sacrificing each group at the specified times [8] .
After adminstration of each dose of the 5 compounds or their respective controls, CF 1 mice were killed by carbon dioxide asphyxiation. After all vital signs had ceased, a midline incision was made from the lower jaw to the inguinal area. The spleen, liver, and kidney were excised and weighed, and then representative tissue samples (6 sections randomly selected from each group) were fixed in 10% buffered formalin, trimmed and sectioned at 6Ix in thickness and stained with hematoxylin and eosin. Abnormal histological/morphological findings were ascertained with light microscopy.
To evaluate in vitro toxicity, (Table II) . Only the 100 mg/kg/day dose reduced daily food consumption. Treated groups showed decreases in total body weight rather than the weight increases usually seen, but the Vol. 1, No. 1, 1993 Some variability occurred in individual organ weights with some exhibiting marked alterations; however average heart, brain, lung, stomach, and reproductive organ weights were relatively stable. Weights of the liver and thymus increased after treatment with 100 mg/kg/day. Small intestine weights were increased at all three doses; conversely, large intestine weights were decreased at all three doses. Histologically at the 20 mg/kg/day dose, (Table II) . Bilirubin, cholesterol, and adolase levels were reduced in a dose- (Table III) . There was no change in daily food consumption; however, a 15% decrease in total body weight was evident at the 100 mg/kg/day dose. The hematocrit values (%) were normal at all dosage levels. (Table Ill) . BUN, cholesterol, aldolas, and CP kinas were reduced in a dose-dependent manner. LDH and tdglycedd levels were increased in a similar fashion. AP and cholic acid levels were raised at lower doses but returned to control values at the 100 mg/kg/day dose. In the differential white blood cell count, lymphocytes increased while PMN levels decreased. Platelet estimates were normal at all doses.
Compound 4_ caused no changes in survival of the animals or in total body weight increases measured after treatment for 7 days (Table IV) . Although daily food consumption was reduced slightly in mice at the 20 mg/kg/day dose, this parameter was within normal limits at the 50 and 100 mg/kg/day doses. Similarly, hematocdt percentages did not differ from control values.
Individual organ weights were normal for the thymus and kidney at all doses of_4. Weights of the heart, lung, brain, small intestine, and large intestine decreased from control values after treatment at the 100 mg/kg/day dose. Spleen weight increased after treatment at 20 mg/kg/day, but returned to control values at 50 and 100 mg/kg/day doses. Increases in weights of the stomach and reproductive organs were directly related to dosage 1v1, indicating a dose-response relationship. Histological examination revealed no visible morphological lesions in the liver and kidney except in mice receiving the 50 mg/kg/day dose. One kidney section showed minor granulomatous inflammation on the capsular surface. Spleen sections in greater than 66% of the mice from all treatment groups including the control showed minute loci of granulomatous inflammation on the capsular surface.
Clinical chemistry values were altered after treatment with Compound _4 (Table IV) . BUN, CP-kinase, bilirubin, uric acid, alkaline phosphatase, and cholic acid showed decreases in values at 100 mg/kg/day. LDH values were elevated at 20 mg/kg/day, and slightly elevated at 50 and 100 mg/kg/day. Serum cholesterol levels were elevated at 100 mg/kg/day, and calcium levels were elevated at 20 mg/kg/day. In the differential white blood cell counts at higher drug concentrations, lymphocytes were increased and PMNs were reduced. Platelet estimates were normal for all groups.
After treatment with Compound 5_, all of the animals survived at all three doses employed ( Table V) . The total body weight increase over 7 days was reduced after treatment with the three doses. Yet, daily food consumption was increased after treatment with 20 and 50 mg/kg/day doses. The hematocrit (%) were normal for animals treated with
Compound _5 at all dosage levels. Individual organ weights were altered by Compound 5_, heart, lung, and stomach weights were reduced at 20 mg/kg/day; these weights returned to normal values at the 50 and 100 mg/kg/day doses. The brain and small intestine were reduced in weight after treatment with the 100 mg/kg/day dose. Weights of the liver, spleen, kidney and the reproductive organs were increased; however, these generally did not follow a doseresponse relationship. Hepatic morphological alterations were not visible after treatment with Compound _5 at either the 20, 50, or 100 mg/kg/day dose, IP for 7 days. After Vol. 1, No. 1, 1993 The HCT-8 ileum culture assay also indicated that Compounds 1-_5 caused no enzymatic leakage from the cells which would suggest organ-specific drug toxicity. The hematocrit (red blood cells) and platelet estimates were normal, suggesting no major effects on the bone marrow hematopoietic system. However, all compounds showed some effects on the differential white blood cell count. In the white blood cell population, more lymphocytes were observed, whereas PMNs were lowered. The total white blood cell population did not appear to be reduced by the agents. Rather, the drug stimulated a shift to more lymphocytes, perhaps in response to the observed increase in inflammation around the spleen mesenteric connective tissue and connective tissue. Perhaps the agents have an immunomodulatory activity that may explain these shifts in white blood cell populations.
The cyanoborane group did not appear to be related to observed histological changes since few changes were observed with Compound 1_, which did not contain the cyanoborane moiety. Yet histological examination of tissues after treatment with Compound 2, which contained the cyanoborane moiety and two triisopropylsilyl protecting groups, showed numerous foci of inflammation. However, the parenchymal sections of the organs were generally normal, indicating that the protecting group probably caused no observable tissue damage.
Compounds 3_ and 4_, cytidine derivatives with triisopropylsilyl protecting groups but no cyanoborane group, demonstrated extensive infection of the spleen and mesentery around the organ. Yet only _5, which contained a cyanoborane group, demonstrated extensive damage to the kidney medullary region and papillae with no damage to liver and spleen.
Among the five derivatives tested, Compound _5 was the most active anti-neoplastic agent.
It is not unusual for anti-neoplastic agents to cause kidney toxicity, particularly those containing metal complexes, cis-platinum. Since the boron atom is not considered a heavy metal in the classical sense, it can be inferred that the cyano group caused kidney toxicity. It is interesting to note that the cyanoborane on the guanine 2_ did not cause nephrotoxicity, whereas the cytidine derivative _5 was toxic to the kidney. Kidney toxicity was not accompanied by concurrently increased levels of BUN at any dose of Compound 5_, which was a peculiar finding. Clinical chemistry values are thought to change before morphological lesions are observable.
